Jim Cramer Sees Value in Thermo Fisher Scientific Amid Market Correction
Thermo Fisher Scientific Inc. (NYSE:TMO) shares fell 9.2% after a recent earnings report, but Jim Cramer argues the stock is cheap at 19 times earnings and poised to benefit from surging IPO activity and AI spending.
Jim Cramer has advised investors to purchase shares of Thermo Fisher Scientific Inc. (NYSE:TMO) at current market levels, describing the valuation as surprisingly cheap. The recommendation comes after the stock experienced a sharp 9.2% decline following the company's recent earnings release. Despite the drop, Cramer argues that the market has mispriced the share, which is currently trading at 19 times earnings.
The host of *Mad Money* highlighted a solid set of numbers reported by the company, noting a healthy 19-cent earnings beat off a $5.25 basis alongside a modest revenue beat. While management raised the full-year forecast substantially, the guidance provided for the current quarter was described as light. Cramer suggested this cautious outlook contributed to the stock's significant plunge, which saw shares fall by $47.28 in a single day.
Cramer's bullish stance relies heavily on the anticipated surge in initial public offerings and artificial intelligence initiatives. He noted that every new IPO mentioned in the market will require Thermo Fisher's instruments and lab services, linking the company's future revenue directly to these broader trends. The host expressed surprise that a company with such strong fundamentals is trading at such a low multiple, stating he sees many IPOs every morning that will need TMO's machines.
Thermo Fisher Scientific provides a wide range of products including instruments, reagents, consumables, software, and lab services that support scientific research, diagnostics, and drug development. Cramer has long regarded the firm as the "arms dealer to the life sciences industry" and has been a consistent fan of the business. He believes the current price point offers a rare opportunity for investors to acquire a great American company at a discount.
The advice was given in response to a caller asking for a buy, sell, or hold rating on the stock. Cramer responded by saying he likes the stock at its current level and that the market has it wrong. This perspective contrasts with some institutional sentiment that has recently favoured other tech giants, with reports indicating heavy buying pressure on shares of companies like NVIDIA and Amazon amid their own strong earnings reports.
While the broader market context involves volatility in biotech and AI-related stocks, Cramer maintains that Thermo Fisher represents a compelling investment case. He emphasised that the company's role in supporting the life sciences sector positions it well to capture value from the ongoing expansion of IPOs and technological spending, regardless of short-term guidance concerns.
